Targeted Oncology1h
Novel immunotherapy FK-PC101 Explored in Prostate Cancer Trial
The phase 2 CELLVX-230 trial is assessing the potential of FK-PC101 to prevent prostate cancer recurrence and delay ...
Targeted Oncology2h
Mechanism of Action Compared With Other Alkylating Agents
Joshua K. Sabari, MD, describes the mechanism of action of lurbinectedin as a synthetic alkaloid that binds to guanine ...